Weren't some of these guys predicting a huge rally? The same geniuses who are predicting 10/20/40 now. I think that even the MM's were surprised by the weakness of the rally, as they would have loved to unload shares at 4. It took prompt intervention and a trading halt to hold it at 3.60
No partners, no licensees = no future. And why has another one of my doppelgangers suddenly appeared to bury factual posts under garbage? What are these guys afraid of? I think that whenever something factual is posted here, an alarm goes off in the basement of the Greybar building and these guys crawl out of the Grand Central tunnels and spew nonsense.
Lasted about 3 minutes on 100,000 shares, then fell right back to 3.60 as they rushed for the exits. Trading was halted, or it would have gone much lower. Then the MM's held it in place at 3.60 (which meant they were selling and buying it there), releasing it in the last 20 minutes, so that it could come up for air. After hours, margin calls took it right down to 3.60 again. Real strong performance on a day when the major averages all rallied 2 1/2%.
Synergy = B-R-O-K-E. Just like that other Jacobs gem, CTRV.
Note that whenever I post something factual, these pathetic doppelgangers, ashamed to post under their own id's, post some ridiculous fantasy, such as "giant advancements in UC". They are so desperate to bury factual posts under their usual mountain of garbage, one wonders what their motives are. What are they afraid of?
I should add that the licensing agreements with Ironwood were fairly lucrative. AstraZeneca gave them an upfront payment of $25 million for the Chinese rights, with another $125 million in milestone payments. Plus a 45/55 split of profits, migrating to 50/50. Astellas paid $15 million upfront for the Japanese rights to linaclotide ..three years before the drug was approved. If plecanatide is so great, why has no one licensed it? They sure could use some cash.
"giant advancements"? All they have is an uncontrolled 4 week study with 24 patients for UC. Because that's all they could afford. There are no clinical trials underway for dolcanatide ...and other than followup monitoring on the CIC trials for Plecanatide, I don't see any action there either. These guys are broke.
PS The fantasy that Linzess users are suffering from diarrhea and will switch to plecanatide at some indefinite point in the future is silly. Linzess works for most of those for whom it is prescribed. If it causes diarrhea, you either move to a lower dose or quit using it.
What big pharma are you talking about? Synergy is essentially broke. If they could have found someone to float a secondary, they would have done it by now. There is only ONE piece of possible good news for Synergy stockholders: a partnership with a major pharma or a buyout. The partnership should have happened years ago ... if anyone was interested. If a buyout happens, it's hard to see how it would command a significant premium.
If everything goes according to the best scenario, plecanatide MIGHT be approved by the FDA for CIC in the US by yearend. Linzess was approved for both CIC and IBS-C on November 12, 2012. However, I would argue that Ironwood is really much further ahead than 4 years.
Ironwood had an original partnership for linalclotide with Forest Labs (now part of Allergan). In 2009, Astellas licensed linaclotide for Japan. In 2012, AstraZeneca licensed it for China. Synergy, to this point, has no licensing/partnership deals in place. Why?
Linzess (as Constella) was approved for Europe on June 13, 2013.
Ironwood has successfully completed separate Phase III trials for linaclotide in both China and Japan. AstraZeneca and Astellas will file for approval in both those markets early this year.
In the US, Ironwood is currently recruiting for 10 clinical trials for Linzess. These include secondary targets, such as pediatric CIC, diabetic gastroparesis, colonic release formulations, etc. Synergy lists 2 trials, both for IBS-C, as recruiting, but there is no sign that they're active. (Remember, Linzess has been approved for IBS-C since late 2012.)
Ironwood is also recruiting for clinical trials for IW1973 and IW1701.
Synergy has a bit of catching up to do.
Yes, they are telling their patients, "i'm writing you a prescription for plectanide. It should be in your pharmacy in about two years, if the FDA approves it, and they can find someone to put up half a billion dollars. But i'm reasonably confident that you'll have a bowel movement by September of 2017."
Hmm. This is one of the posts he tried to delete.
But why did you just remove all those other posts from July and August about how you went to the bio conferences and learned that Valeant was about to acquire this company? I just bumped them up to show what a swell source you are for inside info?
Wow, ...sounds like easy money! Load up at three and sell at 6! What about those here who are already loaded up above 3? With all due respect, "load up at three" is a lousy way to hedge a long bet.
PS Pardon me for injecting items of relevance.
Also, the controlling family, I believe, owns all of the general partnership shares and about 1/4 of the limited partnership shares. Given that fact, I am sure they are attentive to our welfare.
Note that on the most frequented site for drug reviews, in the last six months, there are 34 reviews of Linzess for CIC, and 6 for Amitiza. For IBS, in the last six months, there are 21 for Linzess and 3 for Amitiza.
I think you should look more closely at those reviews. The fact is that a lot of people used to be satisfied with Amitiza ... even though virtually all of them put up with nausea. Almost no one is prescribing Amitiza these days - it has been replaced by Linzess in the US, and will soon be replaced by Linzess (or Constella, its European version) in overseas market.
If he could only have given Paulson a heads-up on Valeant. Could have saved him 3/4 of a $billion.